|
|
|
2395 SHIN NIPPON BIOMEDICAL LABORATORIES,LTD.
|
|
| 02/06/2026 11:30 |
Presentation Materials on Financial Results for the First Nine Months of the Fiscal Year Ending March 31, 2026 |
| 02/06/2026 11:30 |
Consolidated Financial Results for the Nine Months Ended December 31, 2025 (Under Japanese GAAP) |
| 02/06/2026 11:30 |
Notice Concerning Revisions to Full-Year Consolidated Financial Forecasts for the Fiscal Year Ending March 31, 2026 |
| 12/27/2025 00:30 |
SNBL Integrated Report 2025 part2 |
| 12/27/2025 00:30 |
SNBL Integrated Report 2025 part1 |
| 12/27/2025 00:30 |
SNBL ESG Data Book2025 |
| 12/26/2025 11:15 |
Corporate Governance Report |
| 11/07/2025 11:30 |
Presentation Materials for the First Six Months of the Fiscal Year Ending March 31, 2026 |
| 11/07/2025 11:30 |
Notice Regarding Differences between Consolidated Financial Forecasts and Actual Results for the Six Months Ended September 30, 2025 |
| 11/07/2025 11:30 |
Notice Regarding Distribution ofInterim Dividends from Retained Earnings |
| 11/07/2025 11:30 |
Consolidated Financial Results for the Six Months Ended September 30, 2025 (Under Japanese GAAP) |
| 08/05/2025 11:30 |
Presentation materials on Financial Results for the First Three Months of the Fiscal Year ending March 31, 2026 |
| 08/05/2025 11:30 |
Consolidated Financial Results for the Three Months of the Fiscal Year Ending March 31, 2026 (Under Japanese GAAP) |
| 07/01/2025 15:30 |
[Delayed] Corporate Governance Report |
| 06/14/2025 08:00 |
Notice of Convocation of the 52nd Annual General Meeting of Shareholders |
| 05/30/2025 11:30 |
Notice Regarding Distribution of Year-end Dividends from Retained Earnings |
| 05/16/2025 15:30 |
(Corrections/Corrections of Numerical Data) Consolidated Financial Results for the Fiscal Year Ended March 31, 2025 (Under Japanese GAAP) |
| 05/08/2025 11:30 |
Presentation Materials for the Fiscal Year Ended March 31, 2025 |
| 05/08/2025 11:30 |
Consolidated Financial Results for the Fiscal Year Ended March 31, 2025 (Under Japanese GAAP) |
| 05/01/2025 12:10 |
Satsuma Pharmaceuticals Announces U.S. FDA Approval for Atzumi (Dihydroergotamine) Nasal Powder for the Acute Treatment of Migraine |
| 03/28/2025 08:50 |
SNBL and Tasso, Inc. to Establish Joint Venture in Japan |
|